{
    "title": "France's Sanofi still sees COVID-19 phase 3 trial completed in Q1",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10475967/Frances-Sanofi-eyes-COVID-19-shot-approval-helping-grow-2022-earnings.html",
    "date": "2022-02-04",
    "keywords": [
        "covid19",
        "quarter",
        "sanofi",
        "year",
        "chatillon",
        "consumer",
        "drugmaker",
        "vaccine",
        "trial",
        "rise",
        "share",
        "glaxosmithkline",
        "approval",
        "end",
        "healthcare",
        "fouche",
        "paris",
        "phase",
        "fourthquarter",
        "friday",
        "group",
        "comeback",
        "ground",
        "jab",
        "race",
        "increase",
        "doubledigit",
        "whole",
        "exchange",
        "company",
        "world",
        "technology",
        "coronavirus",
        "partner",
        "candidate",
        "approach",
        "mass",
        "half",
        "december",
        "sanofis",
        "officer",
        "today",
        "q1",
        "jeanbaptiste",
        "chasseloup",
        "month",
        "business",
        "bid",
        "gsk",
        "price",
        "consolidation",
        "sector",
        "attempt",
        "part",
        "unit",
        "game",
        "companys",
        "focus",
        "value",
        "division",
        "sudip",
        "kargupta",
        "tomasz",
        "janowski"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}